Use of psychotropic medication during pregnancy and the postpartum period

被引：4

作者：

Pearlstein, Teri ^{[1
]}

机构：

[1] Brown Univ, Alpert Med Sch, Womens Med Collaborat, 146 West River St, Providence, RI 02904 USA

来源：

WOMENS HEALTH | 2013年 / 9卷 / 06期

关键词：

antidepressant; antiepileptic; antipsychotic; birth outcome; congenital malformations; depression; lithium; persistent pulmonary hypertension of the newborn; postnatal adaption syndrome; pregnancy;

D O I：

10.2217/WHE.13.54

中图分类号：

R71 [妇产科学];

学科分类号：

100211 [妇产科学];

摘要：

Women with active psychiatric disorders who become pregnant face treatment dilemmas. Although results from studies are inconsistent, small but significant, risks on birth outcomes occur with exposure to untreated disorders, as well as to psychotropic medications. Prenatal antidepressant medication exposure may increase the risk for spontaneous miscarriage, preterm birth, cardiac malformations, persistent pulmonary hypertension of the newborn and postnatal adaptation syndrome. The use of valproate is contraindicated during pregnancy due to teratogenicity and neurocognitive delay and deficits. This review of selected studies will highlight some of the current issues with the use of psychotropic medications during pregnancy and the postpartum period.

引用

页码：605 / 615

页数：11

共 93 条

[1]

ACOG Committee on Practice Bulletins--Obstetrics, 2008, Obstet Gynecol, V111, P1001, DOI 10.1097/AOG.0b013e31816fd910

[2]

Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands [J].